MDM2 and neuroblastoma: In addition, the nontoxic dose of Nutlin-3a used in this study, which showed immunomodulatory effect in both in vitro and in vivo NB models, as we previously reported (26), or that of its analogues, combined with DNAM-1-engineered NK cells, should be defined in the clinical setting based on the currently applied nontoxic doses of MDM2-targeting drugs reported in several clinical trials for the treatment of different forms of solid tumors (ClinicalTrial.gov and Supplementary Table S2).